title: Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark--secondary publication.
abstract: BACKGROUND
  Data seem to indicate that young adults with acute lymphoblastic leukemia (ALL) have a better survival when treated with pediatric protocols compared with adult ALL protocols. The purpose of the study was to report the clinical characteristics and outcome of all children and young adults 10-19 years of age diagnosed with ALL in Denmark between 1992 and 2001.
  
  
  METHODS
  The study includes 99 patients 10-19 years of age with ALL in Denmark during a ten year period found in the complete NOPHO (Nordic Society of Pediatric Hematology and Oncology) registry and through the Danish Cancer Registry and local pathology databases. Data were retrieved by reviewing medical charts of the patients. A total of 61 children (10-14 years) treated on pediatric protocols and 38 young adults (15-19 years) were diagnosed with ALL. Data were reported as of January 1st 2005.
  
  
  RESULTS
  There were no difference with respect to the distribution of T-ALL, CNS-leukemia, total white blood count and high risk chromosomal abnormalities between the two groups. There was a statistical significant lower event free survival (p<0.01) and lower overall survival (p<0.01) in young adults compared with 10-14 year-old children (0.38 vs 0.60 and 0.47 vs 0.67). There were more transplant-related deaths in the young adults. Higher treatment intensity in children may be an additional explanatory factor. Children received more prednisone, vincristine and high-dose methotrexate than young adults.
  
  
  CONCLUSIONS
  Young adult patients with ALL might benefit from therapy with pediatric NOPHO ALL protocols.
authors.affiliation: Department of Pediatrics, University Hospital of Aarhus, Skejby Hospital, Aarhus, Denmark. hsa@sks.aaa.dk
authors.forename: H
authors.initials: H
authors.lastname: Schrøder
authors.forename: M
authors.initials: M
authors.lastname: Kjeldahl
authors.forename: A M
authors.initials: AM
authors.lastname: Boesen
authors.forename: O J
authors.initials: OJ
authors.lastname: Nielsen
authors.forename: K
authors.initials: K
authors.lastname: Schmidt
authors.forename: H E
authors.initials: HE
authors.lastname: Johnsen
authors.forename: H
authors.initials: H
authors.lastname: Gregersen
authors.forename: M
authors.initials: M
authors.lastname: Heyman
authors.forename: G
authors.initials: G
authors.lastname: Gustafsson
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin